目的:探讨紫杉醇联合顺铂化疗对晚期非小细胞肺癌(NSCLC)患者的疗效,以及对机体免疫功能的影响。方法:回顾分析2009-01/2009-12采用紫杉醇联合顺铂的化疗方案治疗87例晚期NSCLC的临床资料。结果:观察组完全缓解(CR)20.69%,部分缓解(PR)25.29%,无变化(NC)31.03%,进展(PD)22.99%,总有效率45.98%。随访6～12月,缓解期为8.9个月,1年生存率为43.68%。全组在治疗中,未出现因化疗毒性而终止治疗者。但出现不同程度的毒副反应,恶心、呕吐7例,中性粒细胞减少5例,水肿4例,皮疹瘙痒2例,均对症治疗后好转。观察组治疗前化疗前CD4+、CD4+/CD8+阳性细胞比例低于对照组(P<0.05),差异有统计学意义。化疗后CD4+、CD4+/CD8+阳性细胞比例较化疗前均显著升高(P<0.05),差异有统计学意义。结论:紫杉醇联用顺铂是治疗非小细胞肺癌的有效方案,毒副反应可以耐受,使用安全,并且可减少化疗对非小细胞肺癌患者细胞免疫功能的影响。 Objective: To investigate the efficacy of paclitaxel combined with cisplatin chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and its effect on immune function. Methods: The clinical data of 87 patients with advanced NSCLC treated with paclitaxel plus cisplatin during 2009-01 / 2009-12 were retrospectively analyzed. Results: In the observation group, 20.69% of complete remission (CR), 25.29% of partial remission (PR), 31.03% of no change (NC), 22.99% of progression (PD) and 45.98% of total effective rate were observed in observation group. Follow-up from June to December, the remission period was 8.9 months, and the 1-year survival rate was 43.68%. The whole group in the treatment, did not appear due to chemotherapy toxicity and termination of treatment. However, there were different degrees of toxicity, nausea and vomiting in 7 cases, neutropenia in 5 cases, edema in 4 cases and rash pruritus in 2 cases, all improved after symptomatic treatment. The proportion of CD4 + and CD4 + / CD8 + positive cells in the observation group before treatment was lower than that in the control group (P <0.05). The difference was statistically significant. The percentage of CD4 +, CD4 + / CD8 + positive cells after chemotherapy was significantly higher than that before chemotherapy (P <0.05), the difference was statistically significant. CONCLUSION: Paclitaxel combined with cisplatin is an effective treatment for non-small cell lung cancer. Toxicity and side effects can be tolerated, safe to use and can reduce the impact of chemotherapy on cellular immune function in patients with non-small cell lung cancer.